fda warning letters compounded semaglutide tirzepatide 2025 and Novo Nordisk Warned of GLP-1 Telehealth Compounding Takedown. What's Next? FDA Sends 30 Warning Letters

The following interventions were of interest for the network: semaglutide 2.4 mg, || ||||||||| |||||||||| |||| ||| ||||||||| ||||||||||| ||| ||| |||||||| |||| |||||| |||||||||| ||| ||||||||| |||| |||||| ||||||||||| ||| |||||||||| |||| |||||| ||| |||||||||||||| |||||||| || ||||| ||||||||| Efficacy and safety outcomes were captured

GA: Investigation, Methodology, Writing original draft, Writing review & editing

Precautions: Topical use only

500 L-carnitin

Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement